Purchase this article with an account.
J. Hu, E. Blom, P. Bernstein, M. Teske, D. Blanchard, Z. Yang, K. Zhang; Intravitreal Injection of Triamcinolone Acetonide for Macular Edema Due to Various Retinal Vascular Diseases . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4025.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To investigate the efficacy of intravitreal injection of triamcinolone acetonide (TA) for macular edema due to retinal vascular diseases. Methods: One time intravitreal injection of 4 mg TA was given to patients with macular edema due to diabetic clinically significant macular edema (CSME), cystoid macular edema (CME) secondary to Irvine-Gass syndrome and retinal vein occlusions. Patients were followed by visual acuity measurements and foveal thickness analysis using Optic Coherence Tomography (OCT3). Results: We studied 16 patients with chronic macular edema due to the following conditions: CSME (8 patients), Irvine-Gass syndrome (4 patients) and retinal vein occlusions (4 patients). The mean follow up period is 55 days, the mean pre-injection visual acuity is 20/125, the mean post injection visual acuity is 20/70. The mean pre-injection foveal thickness is 415.33 microns, the mean post-injection foveal thickness is 242.4 microns by OCT3 measurements (P value =0.07). Conclusions: Intravitreal TA injection appears to be a promising treatment option for macular edema due to various retinal vascular diseases. Clinical data from a larger cohort with a longer follow up will be presented.
This PDF is available to Subscribers Only